CA3114015A1 - Thyroid hormone receptor beta agonist compounds - Google Patents
Thyroid hormone receptor beta agonist compounds Download PDFInfo
- Publication number
- CA3114015A1 CA3114015A1 CA3114015A CA3114015A CA3114015A1 CA 3114015 A1 CA3114015 A1 CA 3114015A1 CA 3114015 A CA3114015 A CA 3114015A CA 3114015 A CA3114015 A CA 3114015A CA 3114015 A1 CA3114015 A1 CA 3114015A1
- Authority
- CA
- Canada
- Prior art keywords
- substituted
- alkyl
- compound
- cycloalkyl
- halo
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Gastroenterology & Hepatology (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862745195P | 2018-10-12 | 2018-10-12 | |
| US62/745,195 | 2018-10-12 | ||
| PCT/US2019/055689 WO2020077123A1 (en) | 2018-10-12 | 2019-10-10 | Thyroid hormone receptor beta agonist compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3114015A1 true CA3114015A1 (en) | 2020-04-16 |
Family
ID=70161488
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3114015A Pending CA3114015A1 (en) | 2018-10-12 | 2019-10-10 | Thyroid hormone receptor beta agonist compounds |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US11203587B2 (https=) |
| EP (1) | EP3863635A4 (https=) |
| JP (2) | JP7595004B2 (https=) |
| CN (1) | CN112839655B (https=) |
| AR (1) | AR116694A1 (https=) |
| AU (1) | AU2019357618B2 (https=) |
| CA (1) | CA3114015A1 (https=) |
| MA (1) | MA53868A (https=) |
| TW (2) | TWI840423B (https=) |
| WO (1) | WO2020077123A1 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111320609A (zh) | 2018-12-13 | 2020-06-23 | 拓臻股份有限公司 | 一种THRβ受体激动剂化合物及其制备方法和用途 |
| GEP20247637B (en) | 2019-05-08 | 2024-06-25 | Aligos Therapeutics Inc | Modulators of thr-b and methods of use thereof |
| AU2020336272A1 (en) | 2019-08-23 | 2022-04-14 | Terns Pharmaceuticals, Inc. | Thyroid hormone receptor beta agonist compounds |
| CN114375193B (zh) | 2019-09-12 | 2024-05-14 | 拓臻制药公司 | 甲状腺激素受体β激动剂化合物 |
| CN113278013B (zh) * | 2020-02-20 | 2022-09-23 | 昆药集团股份有限公司 | 2,6-二取代的1,2,4-三嗪-3,5-二酮化合物及其制备方法和应用 |
| US20230257367A1 (en) * | 2020-06-02 | 2023-08-17 | Chengdu Kanghong Pharmaceutical Co., Ltd. | Novel thyroid hormone beta receptor agonist |
| WO2022053028A1 (zh) * | 2020-09-10 | 2022-03-17 | 南京明德新药研发有限公司 | 1,2,4-三嗪-3,5(2h,4h)-二酮类化合物及其应用 |
| CN112645936B (zh) * | 2020-12-17 | 2022-03-01 | 山东第一医科大学(山东省医学科学院) | 取代的哒嗪酮类化合物及其用途 |
| CA3212130A1 (en) * | 2021-03-03 | 2022-09-09 | Terns Pharmaceuticals, Inc. | Thyroid hormone receptor beta agonist compounds |
| US20240398794A1 (en) | 2023-04-07 | 2024-12-05 | Terns Pharmaceuticals, Inc. | COMBINATIONS OF GLP-1R AND THRß AGONISTS AND METHODS OF USE THEREOF |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6787652B1 (en) | 1999-09-30 | 2004-09-07 | Pfizer, Inc. | 6-Azauracil derivatives as thyroid receptor ligands |
| EP1088819B1 (en) | 1999-09-30 | 2005-06-15 | Pfizer Products Inc. | 6-azauracil derivatives as thyroid receptor ligands |
| US7230031B2 (en) | 2002-01-30 | 2007-06-12 | Kissei Pharmaceutical Co., Ltd. | Thyroid hormone receptor ligand, medicinal compositions containing the same and use thereof |
| WO2003094845A2 (en) | 2002-05-08 | 2003-11-20 | Bristol-Myers Squibb Company | Pyridine-based thyroid receptor ligands |
| US7572799B2 (en) | 2003-11-24 | 2009-08-11 | Pfizer Inc | Pyrazolo[4,3-d]pyrimidines as Phosphodiesterase Inhibitors |
| FR2882750B1 (fr) * | 2005-03-03 | 2007-05-11 | Pierre Fabre Medicament Sa | Derives de 1,2,4-triazines, leur preparation et leur application en therapeutique humaine |
| GB0513692D0 (en) | 2005-07-04 | 2005-08-10 | Karobio Ab | Novel pharmaceutical compositions |
| PL1919878T3 (pl) * | 2005-07-21 | 2011-03-31 | Hoffmann La Roche | Pochodne pirydazynonu jako agoniści receptora hormonu tarczycy |
| FR2933979B1 (fr) | 2008-07-15 | 2012-08-24 | Pf Medicament | Derives de triazines et uraciles, leur preparation et leur application en therapeutique humaine |
| TWI534144B (zh) | 2009-04-20 | 2016-05-21 | 田邊三菱製藥股份有限公司 | 甲狀腺荷爾蒙β受體作動藥 |
| WO2011038207A1 (en) | 2009-09-25 | 2011-03-31 | Metabasis Therapeutics, Inc. | Phosphorus-containing thyroid hormone receptor agonists and methods of use |
| EP2780338B1 (en) * | 2011-11-14 | 2016-11-09 | Ignyta, Inc. | Uracil derivatives as axl and c-met kinase inhibitors |
| CN103130723B (zh) | 2011-11-30 | 2015-01-14 | 成都地奥制药集团有限公司 | 一种多聚(adp-核糖)聚合酶抑制剂 |
| EP3189046B1 (en) * | 2014-09-05 | 2020-08-26 | Genentech, Inc. | Therapeutic compounds and uses thereof |
| IL266054B2 (en) | 2016-10-18 | 2023-10-01 | Madrigal Pharmaceuticals Inc | Methods for treating liver disorders or lipid disorders using a THR-BETA agonist |
| CN109574995B (zh) | 2018-01-23 | 2020-07-24 | 深圳市塔吉瑞生物医药有限公司 | 取代的哒嗪酮化合物 |
| CN111801324B (zh) | 2018-06-12 | 2021-10-22 | 四川海思科制药有限公司 | 甲状腺激素受体激动剂及其用途 |
| CA3110520A1 (en) | 2018-08-24 | 2020-02-27 | Terns, Inc. | Thyroid hormone receptor beta agonist compounds |
| US12391677B2 (en) | 2018-10-12 | 2025-08-19 | InventisBio Co., Ltd. | Thyroid hormone receptor agonists |
| CN111320609A (zh) | 2018-12-13 | 2020-06-23 | 拓臻股份有限公司 | 一种THRβ受体激动剂化合物及其制备方法和用途 |
| CN111484481A (zh) | 2019-01-26 | 2020-08-04 | 察略盛医药科技(上海)有限公司 | 哒嗪酮类衍生物、其制备方法及其在医药上的用途 |
| US12338206B2 (en) | 2019-02-21 | 2025-06-24 | Nanjing Ruijie Pharma Co., Ltd. | Compounds and their uses as thyroid hormone receptor agonists |
| CN114174282A (zh) | 2019-05-29 | 2022-03-11 | 南京明德新药研发有限公司 | 作为甲状腺素受体-β激动剂的哒嗪酮类衍生物及其应用 |
-
2019
- 2019-10-09 TW TW108136747A patent/TWI840423B/zh active
- 2019-10-09 TW TW113111231A patent/TWI884745B/zh active
- 2019-10-10 CN CN201980067301.7A patent/CN112839655B/zh active Active
- 2019-10-10 US US16/598,978 patent/US11203587B2/en active Active
- 2019-10-10 MA MA053868A patent/MA53868A/fr unknown
- 2019-10-10 JP JP2021519726A patent/JP7595004B2/ja active Active
- 2019-10-10 EP EP19870196.3A patent/EP3863635A4/en active Pending
- 2019-10-10 AU AU2019357618A patent/AU2019357618B2/en active Active
- 2019-10-10 CA CA3114015A patent/CA3114015A1/en active Pending
- 2019-10-10 WO PCT/US2019/055689 patent/WO2020077123A1/en not_active Ceased
- 2019-10-11 AR ARP190102912A patent/AR116694A1/es unknown
-
2022
- 2022-06-30 US US17/855,672 patent/US20220348561A1/en not_active Abandoned
-
2024
- 2024-11-25 JP JP2024204381A patent/JP2025041602A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN112839655B (zh) | 2025-11-25 |
| AR116694A1 (es) | 2021-06-02 |
| TWI884745B (zh) | 2025-05-21 |
| JP2025041602A (ja) | 2025-03-26 |
| US20200115362A1 (en) | 2020-04-16 |
| JP2022504620A (ja) | 2022-01-13 |
| EP3863635A1 (en) | 2021-08-18 |
| MA53868A (fr) | 2021-08-18 |
| US20220348561A1 (en) | 2022-11-03 |
| US11203587B2 (en) | 2021-12-21 |
| TWI840423B (zh) | 2024-05-01 |
| AU2019357618A1 (en) | 2021-04-29 |
| TW202027748A (zh) | 2020-08-01 |
| WO2020077123A1 (en) | 2020-04-16 |
| CN112839655A (zh) | 2021-05-25 |
| TW202430520A (zh) | 2024-08-01 |
| JP7595004B2 (ja) | 2024-12-05 |
| AU2019357618B2 (en) | 2025-04-24 |
| EP3863635A4 (en) | 2022-06-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA3114015A1 (en) | Thyroid hormone receptor beta agonist compounds | |
| JP7846735B2 (ja) | 甲状腺ホルモン受容体ベータアゴニスト化合物 | |
| EP3555070B1 (en) | Amine-substituted heterocyclic compounds as ehmt2 inhibitors and methods of use thereof | |
| CA3154488A1 (en) | Thyroid hormone receptor beta agonist compounds | |
| US20220274961A1 (en) | Substituted fused bi- or tri- heterocyclic compounds as ehmt2 inhibitors | |
| JP2026027279A (ja) | 甲状腺ホルモン受容体ベータアゴニスト化合物 | |
| CA3212130A1 (en) | Thyroid hormone receptor beta agonist compounds | |
| WO2020257527A1 (en) | Compounds for inhibiting fgfr4 | |
| CA3046864C (en) | Cdk4/6 inhibitor |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20220929 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION Effective date: 20240802 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD Year of fee payment: 5 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20240917 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20240917 Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20240917 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20241007 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20250225 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20250225 |
|
| D22 | Grant of ip right intended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D22-D128 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALLOWANCE REQUIREMENTS DETERMINED COMPLIANT Effective date: 20250729 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20250729 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD Year of fee payment: 6 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250916 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250916 |